Compare · MTCR vs RLX
MTCR vs RLX
Side-by-side comparison of Metacrine Inc. (MTCR) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTCR and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.18B, about 145.9x MTCR ($21.8M).
- MTCR has more recent analyst coverage (4 ratings vs 2 for RLX).
- Company
- Metacrine Inc.
- RLX Technology Inc.
- Price
- $0.49-0.50%
- $2.00-1.48%
- Market cap
- $21.8M
- $3.18B
- 1M return
- -
- -6.32%
- 1Y return
- -
- -8.88%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 4
- 2
Metacrine Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest MTCR
- SEC Form 15-12G filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Klassen Preston
- SEC Form S-8 POS filed by Metacrine Inc.
- SEC Form S-8 POS filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Leadership Update
- Metacrine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets
- SEC Form EFFECT filed by Metacrine Inc.
- SEC Form 25-NSE filed by Metacrine Inc.
- SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao